In:
Obstetrical & Gynecological Survey, Ovid Technologies (Wolters Kluwer Health), Vol. 75, No. 3 ( 2020-3), p. 155-157
Abstract:
(Abstracted from Genet Med 2019;21:2293–2302) Noninvasive prenatal screening for aneuploidy using cell-free DNA (cfDNA) has been used since 2011 to identify fetal genetic disorders such as trisomies 13, 18, and 21. However, these tests can give false-positive results or fail all together when other conditions, such as maternal cancer, are present.
Type of Medium:
Online Resource
ISSN:
1533-9866
,
0029-7828
DOI:
10.1097/01.ogx.0000657372.14204.f0
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2020
detail.hit.zdb_id:
2043471-6
Bookmarklink